New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 27, 2018 - Elli Lilly announced the FDA approval of Emgality (galcanezumab-gnlm) for the preventive treatment of migraine in adults.
Download PDF
Return to publications
